Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Enzalutamide + TVB-2640 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Enzalutamide | Xtandi | MDV3100|ASP9785 | Hormone - Anti-androgens 54 | Xtandi (enzalutamide) is a second-generation small molecule inhibitor of androgen receptor, thereby resulting in decreased tumor growth (PMID: 24009414, PMID: 25945058). Xtandi (enzalutamide) is FDA-approved for use in patients with castration-resistant prostate cancer, metastatic hormone-sensitive prostate cancer, and non-metastatic castration-sensitive prostate cancer with biochemical recurrence at high risk for metastasis (FDA.gov). |
TVB-2640 | TVB2640|TVB 2640 | FASN Inhibitor 5 | TVB-2640 is a fatty acid synthase (FASN) inhibitor that inhibits lipid metabolism in tumor cells (PMID: 26519059, PMID: 31630414). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05743621 | Phase I | Enzalutamide + TVB-2640 | Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer | Recruiting | USA | 0 |